Pacira BioSciences, Inc. (PCRX)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
$26.35-0.94%
Close 2026-09-04 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
QuarterlyIQ Insights · PCRX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -19.0% |
| Our one-year growth estimate | diamond | 4.2% |
Growth built into the price is above our model estimate.
The price assumes 23.3 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Model as of 2026-09-04 · Compared with 23 industry peers · Company calendar date is not available
PCRX — divestiture
Dated 2026-06-30
Entry Into a Material Definitive Agreement. On June 28, 2026, Pacira BioSciences, Inc. (the “Company”) and Pacira CryoTech, Inc., the Company’s wholly owned subsidiary (the “Subsidiary”), entered into a Stock and Asset Purchase Agreement (the “Purchase Agreement”) with Zimmer, Inc. (the “Purchaser”), a subsidiary of Zimmer Biomet Holdings, Inc. (“Zimmer Biomet”). Pursuant to the Purchase Agreement, the Company has agreed to divest to the Purchaser (i) all of the issued and outstanding capital…
Why it matters: Cash flow from the divestiture will impact future investments and growth strategies.
Watch forCash flow from the iovera sale is over $70 million in total payments.
Also watch forCash flow from the iovera divestiture is less than $70 million in total payments.
Why it matters: Keeping gross margin in line with guidance shows good cost control and efficiency.
Supportive ifNon-GAAP gross margin remains between 77% and 79% in Q2 2026.
Worry ifNon-GAAP gross margin falls below 77% in Q2 2026.
Why it matters: If sector revenue growth drops, it may show bigger problems for Pacira's performance.
Worry ifSector revenue growth reported below its median of 1% year over year.
Less concerning ifSector revenue growth remains above its median of 1% year over year.
Why it matters: Good news could boost investor trust in Pacira's pipeline and future growth.
Watch forUpdates show progress in the Phase 2 study of PCRX-201 with good efficacy data.
Also watch forUpdates reveal setbacks or delays in the Phase 2 study of PCRX-201.
Why it matters: Hitting the sales target shows that the market likes the product. This helps revenue grow.
Supportive ifEXPAREL net product sales reach between $600 million to $620 million in 2026.
Worry ifIf sales drop below $600 million, it shows demand is weaker.
Why it matters: Ongoing revenue growth shows the 5x30 strategy is working. It also shows products are accepted.
Supportive ifQ3 total revenue growth meets or exceeds 6% year-over-year.
Worry ifQ3 total revenue growth falls below 5% year-over-year.
Why it matters: Good results could lead to a new treatment for shoulder osteoarthritis. This would increase sales.
Supportive ifTopline results from the Phase 3 study of ZILRETTA are reported as positive.
Worry ifTopline results from the Phase 3 study of ZILRETTA are reported as negative.
Why it matters: Positive data could enhance the pipeline and long-term growth outlook.
Supportive ifPositive results from Part A of the Phase 2 study of PCRX-201 for knee osteoarthritis.
Worry ifNegative results or delays in the Phase 2 study of PCRX-201.
Why it matters: Growth in EXPAREL sales is important for reaching revenue goals. It shows market acceptance.
Supportive ifEXPAREL net product sales grow year over year by more than 3%.
Worry ifEXPAREL net product sales decline year over year or grow less than 3%.
Why it matters: Good results could lead to a new use for ZILRETTA. This would help its market.
Supportive ifThe ZILRETTA Phase 3 study shows it is safe and works well for shoulder pain.
Worry ifZILRETTA Phase 3 study results are negative or unclear.
Why it matters: Payments from the iovera sale could bring in more cash. This would support the strategy.
Supportive ifPacira gets payments from Zimmer Biomet for iovera.
Worry ifNo payments are received or there are delays in expected payments.
Why it matters: Topline data will show how well PCRX-201 can be sold in the future.
Watch forTopline data from Part A of the Phase 2 ASCEND study shows good results.
Also watch forTopline data shows no strong results or delays in reporting.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$135 on $10,000 · ±1.3% | How much price usually moves either way. |
| Bad day | $381 loss on $10,000 · 3.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,935 loss on $10,000 · 29.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.